Stock market week-in-review for 5 large GI companies — Sept. 11-15

Here is how five major, publicly traded gastroenterology companies fared in the stock market for the week of Sept. 11 to Sept 15, 2017.

Advertisement

Note: This data was compiled using Google Finance.

1. Allergan Pharmaceuticals

Opened: $236.08 on Sept. 11
Peaked at open
Closed: $ 220.07 on Sept. 15
Percent change between Sept. 11 and Sept. 15: -6.78 percent

2. Exact Sciences Corp.

Opened: $43.39 on Sept. 11
Peaked at open
Closed: $42.80 on Sept. 15
Percent change between Sept. 11 and Sept. 15: -1.35 percent

3. Johnson & Johnson

Opened: $131.34 on Sept. 11
Peaked: $125.19 on Sept. 15
Closed: $134.54 on Sept. 15
Percent change between Sept. 11 and Sept. 15: 2.43 percent

4. Synergy Pharmaceuticals

Opened: $2.80 on Sept. 11
Peaked: $2.89 on Sept. 12
Closed: $2.70 on Sept. 15
Percent change between Sept. 11 and Sept. 15: -3.47 percent

5. Valeant Pharmaceuticals

Opened: $14 on Sept. 11
Peaked: $14.60 on Sept. 12
Closed: $13.90 on Sept. 15
Percent change between Sept. 11 and Sept. 15: -0.71 percent

More articles on gastroenterology: 
How Exact Sciences’ Cologuard has a higher compliance rate than traditional CRC screening method
GI leader to know: Dr. Timothy Halterman of Gastroenterology Consultants
National Institute of Environmental Health Sciences awards Dr. Matthew Cave $4.01M grant — 5 key notes

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

  • Gastroenterology continues to evolve rapidly as advances in colorectal cancer prevention, inflammatory bowel disease research, microbiome science and outpatient digestive…

Advertisement

Comments are closed.